US WorldMeds Finalizes Acquisition of Adaptimmune's Cell-Therapy Portfolio, Paving the Way for Future Innovations US WorldMeds has completed its acquisition of Adaptimmune's cell-therapy assets, ensuring uninterrupted patient access to TECELRA and advancing lete-cel development.

US WorldMeds Finalizes Acquisition of Adaptimmune's Cell-Therapy Portfolio, Paving the Way for Future Innovations #United_States #Louisville #US_WorldMeds #Adaptimmune #TECELRA